Tempero Bio, a biotechnology company based in Oakland, California, has secured $70 million to advance a drug it’s developing into mid-stage testing for cocaine and alcohol use disorders.

总部位于加利福尼亚州奥克兰的生物技术公司Tempero Bio已获得7000万美元，用于推进其正在开发的一种药物进入中期测试，以治疗可卡因和酒精使用障碍。

The Series B round, announced by Tempero Monday, will support two Phase 2 trials of the drug, called TMP-301. The biotech will also use the funds to prepare for late-stage studies as well as to explore additional indications and formulations.

Tempero周一宣布的B轮融资将支持该药物（称为TMP-301）的两项二期临床试验。这家生物技术公司还将利用这笔资金为晚期研究做准备，并探索更多的适应症和配方。

The round was led by investor 8VC, and also involved Khosla Ventures and Aditum Bio, among others.

本轮融资由投资方8VC领投，Khosla Ventures和Aditum Bio等也参与其中。

A relatively new investor in biotech, Aditum previously backed Versanis Bio, an obesity drug developer acquired by

一家相对较新的生物技术投资者，Aditum此前曾支持过被收购的肥胖症药物开发商Versanis Bio，

Eli Lilly in 2023

礼来公司，2023年

. The investment firm is run by former Novartis CEO Joe Jimenez and Mark Fishman, formerly head of Novartis Institutes for BioMedical Research.

这家投资公司由前诺华首席执行官乔·希门尼斯和前诺华生物医学研究所所长马克·菲什曼经营。

Aditum launched

Aditum 推出

Tempero

调料

in 2020 via a partnership with the pharmaceutical company Sosei Heptares. Sosei licensed TMP-301 to Tempero in exchange for an upfront payment and equity stake, while Aditum put up Tempero’s initial funding.

2020年，通过与制药公司Sosei Heptares的合作达成。Sosei公司将TMP-301授权给Tempero，以换取预付款和股权，而Aditum提供了Tempero的初始资金。

According to Tempero, TMP-301 is designed to “address neurobiological basis of addiction” by reducing excessive signaling via a neurotransmitter called glutamate. More specifically, TMP-301 modulates the metabotropic glutamate receptor 5, which is involved in

根据特佩罗的说法，TMP-301 旨在通过减少一种叫做谷氨酸的神经递质的过度信号传导来“解决成瘾的神经生物学基础”。 更具体地说，TMP-301 调节代谢型谷氨酸受体 5，该受体参与

central nervous system function

中枢神经系统功能

.

。

Tempero said the drug showed potential in preclinical models of opiate, alcohol and cocaine use disorders. It has been tested in about 80 healthy individuals as part of a Phase 1 study.

Tempero 表示，这种药物在阿片类、酒精和可卡因使用障碍的临床前模型中显示出潜力。它已在约 80 名健康个体中作为第一阶段研究的一部分进行了测试。

“Substance use disorders affect 48 million Americans and contribute to more than 100,000 deaths per year.  We urgently need more effective treatments to help patients and families with these diseases,” Tempero CEO Ricardo Dolmetsch said in a statement.

“物质使用障碍影响着4800万美国人，并导致每年超过10万人死亡。我们迫切需要更有效的治疗方法来帮助这些疾病患者及其家庭，”Tempero首席执行官里卡多·多尔梅茨在一份声明中表示。

While psychiatry drugs have regained

虽然精神科药物已经重新

investor and drugmaker attention

投资者和制药商的关注

in recent years, the pipeline of novel treatments for substance use disorders remains thin. One new area of promise is the GLP-1 drugs currently used for diabetes and weight loss. Their makers are now studying their effects in

近年来，物质使用障碍的新疗法管线仍然匮乏。一个充满希望的新领域是目前用于糖尿病和减肥的GLP-1药物。其制造商正在研究它们在

curbing alcohol use

控制酒精使用

.

。